{
  "id": "clinical-outcomes-overview",
  "display_name": "Clinical Outcomes",
  "cohort": "Patients with metastatic solid tumors initiating 1st Line treatment (2024-2025)",
  "insight_type": "Clinical Outcomes by Provider",
  "summary": "Overall survival rates show 5% variation across sites, with significant differences in progression-free survival by regimen and provider.",
  "chart_data": {
    "categories": ["Provider A", "Provider B", "Provider C", "Provider D", "Provider E"],
    "values": [60, 57, 54, 58, 56],
    "peer_values": [65, 65, 65, 65, 65],
    "target_values": [70, 70, 70, 70, 70]
  },
  "benchmark": 65,
  "financial_impact": 0,
  "financial_impact_description": "Standardizing outcomes could lead to improved patient care without direct financial impact.",
  "action_steps": [
    "Compare outcomes by regimen and disease subtype",
    "Analyze progression-free survival by provider",
    "Identify best practices from top-performing providers"
  ],
  "drilldowns": [
    {
      "label": "View by Payer Type",
      "description": "Compare outcomes by payer type",
      "jsonFile": "clinical-outcomes-by-payer.json",
      "drilldownLevel": 1
    },
    {
      "label": "Compare Sites",
      "description": "Compare outcomes by site",
      "jsonFile": "clinical-outcomes-by-site.json",
      "drilldownLevel": 1
    },
    {
      "label": "Variance by Regimen",
      "description": "Compare outcomes by regimen",
      "jsonFile": "clinical-outcomes-by-regimen.json",
      "drilldownLevel": 1
    }
  ]
} 